Trial Profile
Analysis of intratumoral immune response early on Nivolumab treatment in unresectable advanced or recurrent gastric cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 13 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.
- 20 Oct 2017 New trial record